/lifesciences?utm_source=rss&utm_medium=rss&utm_campaign=section Latest articles for: Life Sciences Copyright 2025 ÃÛÌÒÊÓƵ. en-US Fri, 11 Jul 2025 22:53:26 +0000 /lifesciences/articles/2363701?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363701 The announcement of federal subpoenas targeting doctors who offer gender-affirming care signals an escalation in the Trump administration's campaign against such treatment, experts say, delivering a warning to healthcare providers. Fri, 11 Jul 2025 22:20:21 +0000 /lifesciences/articles/2363794?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363794 Acting U.S. Patent and Trademark Office Director Coke Morgan Stewart and a top administrative patent judge issued 15 discretionary denial decisions on Patent Trial and Appeal Board petitions over the past week, across nearly 40 cases. Here's what she decided. Fri, 11 Jul 2025 21:51:27 +0000 /lifesciences/articles/2363845?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363845 AbbVie on Thursday defeated a certified securities class action that accused it of giving healthcare providers unlawful kickbacks in exchange for prescribing its flagship arthritis drug Humira when an Illinois federal judge ruled that AbbVie provided legitimate services that were "integrally tied" to the drug itself. Fri, 11 Jul 2025 20:50:11 +0000 /lifesciences/articles/2363860?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363860 Amgen urged a Delaware federal judge in documents made public Friday to overturn a nearly $407 million antitrust and tortious-interference verdict in favor of Regeneron, saying there was a serious lack of evidence shown to the jury. Fri, 11 Jul 2025 20:33:08 +0000 /lifesciences/articles/2362042?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362042 In the two weeks since the U.S. Supreme Court curtailed federal judges' ability to issue universal injunctions, Trump administration attorneys have begun pushing to expand the decision's limits to other forms of relief used in regulatory challenges and class actions. So far, judges don't appear receptive to those efforts.  Fri, 11 Jul 2025 20:15:55 +0000 /lifesciences/articles/2363955?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363955 Physicians asked the U.S. Supreme Court to review a decision immunizing Merck & Co. from antitrust claims over submissions it made to federal regulators over its mumps vaccine, arguing the Third Circuit went far beyond its peers in holding that deceiving the government isn't illegal if the deception worked. Fri, 11 Jul 2025 20:10:11 +0000 /lifesciences/articles/2363782?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363782 The Federal Circuit appeared somewhat skeptical Friday that an orthopedic surgeon held onto the rights of knee replacement patents that he disputably assigned elsewhere, which would endanger the $20 million infringement verdict he won against a Johnson & Johnson unit. Fri, 11 Jul 2025 19:45:44 +0000 /lifesciences/articles/2363983?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363983 The Third Circuit on Friday revived a proposed class action against Mazie Slater Katz & Freeman LLC attorneys that claims they took excessive fees from plaintiffs' settlements in multidistrict litigation over the blood pressure drug Benicar, remanding the dispute for the district court to determine whether it has jurisdiction over the case. Fri, 11 Jul 2025 19:33:26 +0000 /lifesciences/articles/2363737?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363737 An attorney for a nurse fired from the American Red Cross after being denied religious accommodation from the COVID-19 vaccine mandate asked a Detroit federal jury Friday for more than $6 million in damages for what he said was the organization's disregard of the woman's beliefs. Fri, 11 Jul 2025 18:52:20 +0000 /lifesciences/articles/2363018?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363018 Life sciences parties should utilize due diligence strategically to review and draft deal documents, address issues identified during the diligence, and craft solutions to achieve the party's transactional goals, says Anna Zhao at Gunner Cooke. Fri, 11 Jul 2025 18:51:16 +0000 /lifesciences/articles/2363289?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363289 South African Olympic gold medal-winning runner Caster Semenya was deprived of her right to a fair hearing by a Swiss federal court when she appealed testosterone limits imposed on female athletes by track and field's international governing body, the European Court of Human Rights has ruled. Fri, 11 Jul 2025 18:39:38 +0000 /lifesciences/articles/2363993?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363993 Justices overturned a trademark award of more than $40 million in a long-running case in which lower courts put a company's affiliates on the hook for the amount, and a pair of precedential decisions from the Federal Circuit provided guidance on whether colors can be protected trade dress. Here is Law360's list of the biggest trademark decisions so far this year. Fri, 11 Jul 2025 18:39:18 +0000 /lifesciences/articles/2363187?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363187 When Merck agreed to purchase respiratory disease-focused Verona Pharma plc for $10 billion, it became one of Merck's largest deals ever, and the pharmaceutical giant made clear that its bet on a potentially transformative pulmonary therapy was much more than a speculative pipeline acquisition. Fri, 11 Jul 2025 17:50:03 +0000 /lifesciences/articles/2361858?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2361858 Artificial intelligence systems' integration into business operations creates new considerations for intellectual property due diligence in mergers and acquisitions and financing transactions, and implementing a practical approach to identifying AI assets can help avoid litigation and losses, say Armin Ghiam and Senna Hahn at Hunton. Fri, 11 Jul 2025 17:46:50 +0000 /lifesciences/articles/2363743?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363743 A Delaware federal judge on Friday found that Novartis couldn't show that MSN Pharmaceuticals Inc. infringed a patent related to its blockbuster drug Entresto, the latest in the company's wide-ranging fight to keep a generic version of the product off the market. Fri, 11 Jul 2025 16:54:08 +0000 /lifesciences/articles/2363924?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363924 Walgreens Boots Alliance said Friday its shareholders have approved a plan for the company to be purchased by private equity firm Sycamore Partners, in a transaction with a total value of up to $23.7 billion. Fri, 11 Jul 2025 16:46:30 +0000 /lifesciences/articles/2363946?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363946 A California federal judge imposed almost $3 million in sanctions on Quinn Emanuel Urquhart & Sullivan LLP for what he called the firm's "deliberate misrepresentations" concerning an expert witness in a false advertising suit between medical testing company Guardant Health and rival Natera. Fri, 11 Jul 2025 16:45:40 +0000 /lifesciences/articles/2362198?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362198 Amid the U.S. Supreme Court's ruling in McLaughlin Chiropractic Associates v. McKesson, we can expect to see both plaintiffs and defendants utilizing the decision to revisit the Federal Communications Commission's past Telephone Consumer Protection Act interpretations and decisions they did not like, says Jason McElroy at Saul Ewing. Fri, 11 Jul 2025 16:39:30 +0000 /lifesciences/articles/2363483?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363483 Defunct telehealth provider Better Therapeutics Inc. has reached a roughly $1 million settlement with a shareholder to end a Delaware Chancery Court suit challenging its take-public merger, according to court filings. Fri, 11 Jul 2025 16:25:21 +0000 /lifesciences/articles/2363705?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363705 Clinical-stage biopharmaceutical company BridgeBio Oncology Therapeutics, advised by Goodwin Procter LLP, and White & Case LLP-led special purpose acquisition company Helix Acquisition Corp. II on Friday revealed that their $949 million merger had been cleared by U.S. regulators.